Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Cullinan Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Biological Products, (No Diagnostic Substances)
No intraday reading yet this session.
Cullinan Therapeutics, Inc. has 7 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either Cullinan Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Chongqing Genrix Biopharmaceutical Co., Ltd. ("Genrix"), from which we licensed velinotamig, is enrolling a Phase 1 clinical trial in China in patients with autoimmune diseases, initially in patients with SLE, followed by planned future expansion into other indications, and initial clinical data will be shared in the fourth quarter of 2026.”
FILING10-K0001193125-26-099362cik 0001789972
“CLN-418 is a B7H4x4-1BB bispecific antibody that we licensed from Harbour BioMed US Inc. ("Harbour") and were previously evaluating in a Phase 1 clinical trial.”
FILING10-K0001193125-26-099362cik 0001789972
“Pursuant to a co-development agreement, we are collaborating with a Taiho affiliate to develop zipalertinib for the treatment of a genetically defined subset of patients with NSCLC, and Taiho will commercialize zipalertinib.”
FILING10-K0001193125-26-099362cik 0001789972
“Zipalertinib (CLN-081/TAS6417), on which we are collaborating with an affiliate of Taiho Pharmaceutical Co., Ltd. ("Taiho"), is an orally-available small-molecule, irreversible epidermal growth factor receptor ("EGFR") inhibitor that is designed to selectively target cells expressing EGFR exon 20 insertion mutations ("EGFR ex20ins") with relative sparing of cells expressing wild-type EGFR.”
FILING10-K0001193125-26-099362cik 0001789972
“We are party to an exclusive license agreement (the "DKFZ/Tübingen License Agreement") for CLN-049 through our CLN-049 development subsidiary, Cullinan Florentine Corp. ("Cullinan Florentine"), with Deutsches Krebsforschungszentrum ("DKFZ"), Eberhard Karls University of Tübingen, Faculty of Medicine ("University of Tübingen"), and Universitätsmedizin Gesellschaft für Forschung und Entwicklung mbH, Tübingen ("UFE").”
FILING10-K0001193125-26-099362cik 0001789972
“We are party to an exclusive license agreement (the "DKFZ/Tübingen License Agreement") for CLN-049 through our CLN-049 development subsidiary, Cullinan Florentine Corp. ("Cullinan Florentine"), with Deutsches Krebsforschungszentrum ("DKFZ"), Eberhard Karls University of Tübingen, Faculty of Medicine ("University of Tübingen"), and Universitätsmedizin Gesellschaft für Forschung und Entwicklung mbH, Tübingen ("UFE").”
FILING10-K0001193125-26-099362cik 0001789972
“We have a collaboration agreement (the "Adimab Collaboration Agreement"), with Adimab, LLC ("Adimab").”
FILING10-K0001193125-26-099362cik 0001789972
“We had an exclusive patent license agreement (the "MIT License Agreement") for the technology underlying CLN-617 with MIT through our development subsidiary, Cullinan Amber Corp. ("Cullinan Amber").”
FILING10-K0001193125-26-099362cik 0001789972
Watchlist prices, news filtered to it, and its next report on your desk.
CGEM (Cullinan Therapeutics, Inc.) has 7 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.